Tapit (granisetron)
/ VHB Life Sci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
April 10, 2025
Identification of potential cell surface targets in patient-derived cultures toward photoimmunotherapy of high-grade serous ovarian cancer.
(PubMed, Photochem Photobiol)
- "Notably, TFRC was overexpressed in 100% (N = 5) of the patient-derived HGSOC models tested, whereas only 60% of models had high EpCAM expression, suggesting that future larger cohort studies should include TFRC. While this study focuses on target identification, future work will expand the approaches developed here to larger HGSOC biopsy repositories and will also develop and evaluate antibody-photosensitizer conjugates targeting these proteins for taPIT applications."
IO biomarker • Journal • Dyslipidemia • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • EGFR • EPCAM • FOLR1 • LRP1
May 10, 2024
Methods for assessing and removing non-specific photoimmunotherapy damage in patient-derived tumor cell culture models.
(PubMed, Photochem Photobiol)
- "In this study, we tested two primary ovarian tumor cell lines that are intrinsically chemoresistant, yet ultrasensitive to BPD-PDT such that small amounts of free BPD (a few percent of the total BPD dose) lead to potent induction of cell death upon irradiation. The modifications in the protocol suggested here improve in vitro taPIT experiments that lack in vivo mechanisms of free BPD clearance (i.e., lymph and blood flow)."
Journal • Preclinical • Tumor cell • Oncology • Ovarian Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1